GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Net Income Including Noncontrolling Interests

BCAL Diagnostics (ASX:BDX) Net Income Including Noncontrolling Interests : A$-5.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

BCAL Diagnostics's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was A$-2.41 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was A$-5.00 Mil.


BCAL Diagnostics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for BCAL Diagnostics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Net Income Including Noncontrolling Interests Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Net Income Including Noncontrolling Interests
-3.39 -5.06

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial -1.32 -2.07 -2.47 -2.59 -2.41

BCAL Diagnostics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-5.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BCAL Diagnostics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.